PEPG - NASDAQ

PepGen Inc.

PEPG·NASDAQ

$1.45

+4.1%

HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$100.30M

EPS-2.1200

P/E Ratio-3.07

Earnings Date08/06/2026

pepg

Cash and Cash Equivalents

Last Annual Value

60.51M

3-Year CAGR

-31%

5-Year CAGR

44%

10-Year CAGR

33%

Adjust for Inflation

PepGen Inc. Competitors Analysis of Cash and Cash Equivalents

PEPG · NASDAQ

Company	Cash and Cash Equivalents	CAGR 3Y	CAGR 5Y	CAGR 10Y
PepGen Inc. NASDAQ:PEPG	60.51M	-9.2%	-14.6%	N/A
Cardiff Oncology, Inc. NASDAQ:CRDF	17.47M	-6.9%	7.9%	-7.5%
Alector, Inc. NASDAQ:ALEC	65.80M	-4.1%	-27.5%	2.6%
Nkarta, Inc. NASDAQ:NKTX	39.63M	8.5%	-8.2%	N/A
Applied Therapeutics, Inc. NASDAQ:APLT	79.40M	16.7%	8.1%	N/A
Actuate Therapeutics Inc NASDAQ:ACTU	13.16M	64.5%	N/A	N/A
Alto Neuroscience, Inc. NYSE:ANRO	176.48M	28.8%	47.0%	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	74.60M	-16.2%	-0.4%	N/A
Nuvectis Pharma, Inc. NASDAQ:NVCT	31.63M	18.3%	40.7%	N/A
Instil Bio, Inc. NASDAQ:TIL	6.64M	-10.3%	-29.3%	N/A
Cassava Sciences, Inc. NASDAQ:SAVA	95.50M	-7.6%	-16.4%	17.7%

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.45, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

HIDDEN

Intrinsic Value

Current Price: $1.45

Related Guides

Blog Categories

Continue your PEPG research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.